Shares of Moderna (NASDAQ: MRNA) climbed 8.4% on Thursday after the drugmaker said it was gearing up for a potential launch of its experimental COVID-19 vaccine.
Moderna has already received $1.1 billion in customer deposits for its coronavirus vaccine candidate, mRNA-1273. "We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world," CEO Stéphane Bancel said in the biotech's third-quarter earnings release.
Moderna's stock rose on Thursday as investors looked ahead to a possible global launch of its COVID-19 vaccine. Image source: Getty Images.
Source Fool.com